��Ƶ

Immunomodulatory signal presentation via synthetic hydrogel material promotes generation of T regulatory cells (green) in the local graft microenvironment (CD3+ T cells in red, and nuclei staining in blue) after implantation into a clinically relevant transplant model for the treatment of type 1 diabetes. (Credit: Georgia Tech)

Advancing our Health

UofL-born technology for treating Type 1 diabetes has commercial partner

Baylee Pulliam - August 6, 2020

A University of Louisville-born therapy that helps people with Type 1 diabetes stay off immunosuppressants by re-educating the body’s immune system to accept transplanted...